Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

NCT07686796 is registered in ClinicalTrials.gov with Guangdong Provincial People's Hospital as lead sponsor.

NCT NCT07686796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07686796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
Lead sponsor
Guangdong Provincial People's Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
January 1, 2035
Enrollment
148 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

capecitabine, local advanced rectal cancer, oxaliplatin, pcsk9 inhibitor, pd-1 inhibitor, radiotherapy, rct